Looking Into Tempus AI Inc's Recent Short Interest
Tempus AI Inc's (NYSE: TEM) short interest has increased by 6.65% since its last report, with 21.40 million shares sold short, representing 16.68% of its tradable shares. This elevated short interest, which is higher than its peer group average of 6.71%, suggests a more bearish sentiment among investors towards the company. Short interest is an important indicator for gauging market sentiment, as growing short positions often signal that investors anticipate a stock's price to decline.
Tempus AI IPS Study Points To Wider Immunotherapy Use And Investor Interest
Tempus AI (NasdaqGS:TEM) announced new study results for its Immune Profile Score (IPS) test, which showed improved prediction of immunotherapy outcomes compared to conventional biomarkers. This could expand access to immune checkpoint inhibitor therapy and has attracted investor interest due to its potential in diagnostics, oncology, and AI-enabled clinical decision support. The company's IPS update aligns with its strategy to leverage rich oncology data and AI for growth, however, challenges include profitability, reimbursement, and competition from larger diagnostic players.
How Is The Market Feeling About Tempus AI Inc?
Tempus AI Inc's short interest has increased by 10.84% since its last report, with 20.07 million shares sold short, representing 15.64% of its float. This rise indicates a more bearish sentiment among investors compared to the last report. The company's short interest is significantly higher than its peer group average of 6.33%, suggesting a notable level of negative market sentiment.
Tempus AI, Inc. Stock (TEM) Opinions on FDA Clearance and Financial Results
The article discusses recent excitement surrounding Tempus AI, Inc. (TEM) due to its FDA 510(k) clearance for AI-driven diagnostic tools, particularly in oncology, despite a recent 9% stock price drop. It highlights impressive preliminary 2025 revenue of $1.27 billion and details significant insider selling activity, hedge fund movements, government contracts, and positive analyst ratings with a median price target of $87.0.
Stock Market Today: Dow Jones, S&P 500 Futures Tumble As DOJ Serves Federal Reserve—Vistra, Tempus AI, Alibaba In Focus
U.S. stock futures declined on Monday, influenced by rising tensions between the Department of Justice and the Federal Reserve regarding Chairman Jerome Powell's testimony, and a slight miss on nonfarm payrolls. Despite the market dip, several individual stocks including Vistra, Alibaba, Tempus AI, and Xpeng saw premarket gains due to positive company-specific news. Upcoming economic data releases and analyst insights, particularly from Mohamed El-Erian, suggest continued market volatility and a focus on inflation trends and the geopolitical landscape.
Tempus AI Reports Strong Preliminary 2025 Revenue Growth
Tempus AI reported strong preliminary unaudited financial results for the full year and fourth quarter ended December 31, 2025. The company saw an 83% year-over-year revenue increase to approximately $1.27 billion for the full year, driven by significant growth in both its Diagnostics and Data and Applications segments. Management highlighted 2025 as an exceptional year, with both core product lines entering 2026 with accelerating growth and improving financial leverage, reinforcing Tempus AI's position in AI-driven precision medicine.
Tempus AI’s Earnings Call Highlights Strong Growth Amid Challenges
The provided content is empty, so a summary cannot be generated. This indicates an error in the input content, as no article text was found.
Fukushima, Tempus AI COO, sells $321k in shares By Investing.com
Ryan Fukushima, COO of Tempus AI (NASDAQ:TEM), sold 5,000 shares for $321,300 on January 5, 2026, under a Rule 10b5-1 trading plan. Despite the sale, Tempus AI shares have climbed, reflecting strong momentum and an 18% gain over the past week, though InvestingPro analysis suggests the stock is overvalued. The company recently reported better-than-expected Q3 2025 earnings and announced a partnership with the Institute for Follicular Lymphoma Innovation.
Fukushima, Tempus AI COO, sells $321k in shares
Ryan Fukushima, COO of Tempus AI (NASDAQ:TEM), sold 5,000 shares for $321,300 on January 5, 2026. This sale occurred under a Rule 10b5-1 trading plan, despite the stock showing strong momentum with an 18% gain over the past week. Tempus AI recently exceeded Q3 2025 earnings and revenue expectations, although its stock declined post-earnings due to future guidance concerns, leading to mixed analyst price target adjustments.
Fukushima, Tempus AI COO, sells $321k in shares By Investing.com
Ryan Fukushima, COO of Tempus AI, sold 5,000 shares for $321,300 on January 5, 2026, under a Rule 10b5-1 plan. Despite the sale, his indirect and direct holdings remain substantial, and Tempus AI's stock has seen an 18% weekly gain and a 79% annual return, though InvestingPro analysis suggests it may be overvalued. The company recently exceeded Q3 2025 earnings and revenue expectations and announced a research partnership.
Fukushima, Tempus AI COO, sells $321k in shares By Investing.com
Ryan Fukushima, COO of Tempus AI, Inc. (NASDAQ:TEM), sold 5,000 shares of Class A Common Stock for $321,300 on January 5, 2026, under a Rule 10b5-1 trading plan. The sale occurred after an 18% stock gain in the preceding week, with Tempus AI's stock showing a strong 79% return over the last year despite InvestingPro analysis suggesting it is overvalued. The company recently reported better-than-expected Q3 2025 earnings and announced a research partnership with the Institute for Follicular Lymphoma Innovation (IFLI).
Fukushima, Tempus AI COO, sells $321k in shares By Investing.com
Ryan Fukushima, COO of Tempus AI, sold 5,000 shares of Class A Common Stock for $321,300 on January 5, 2026. This transaction occurred under a Rule 10b5-1 trading plan, and Fukushima continues to hold a significant number of shares both directly and indirectly. Despite the sale, Tempus AI's stock has seen an 18% gain in the past week, though analysis suggests it may be overvalued.
Fukushima, Tempus AI COO, sells $321k in shares
Ryan Fukushima, Chief Operating Officer of Tempus AI, Inc., sold 5,000 shares of Class A Common Stock worth $321,300 on January 5, 2026. This sale, conducted under a Rule 10b5-1 plan, occurred as Tempus AI (NASDAQ:TEM) shares climbed, showing impressive year-over-year gains despite being considered overvalued by InvestingPro. The company recently exceeded Q3 2025 earnings expectations and announced a research partnership with the Institute for Follicular Lymphoma Innovation.
TEMPUS AI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - T
Kahn Swick & Foti, LLC (KSF) is reminding investors of Tempus AI, Inc. (NasdaqGS: TEM) who suffered losses exceeding $100,000 of the lead plaintiff deadline on August 12, 2025, in a securities class action lawsuit. The lawsuit alleges that Tempus AI and its executives failed to disclose material information during the Class Period, specifically regarding overstated AI capabilities, aggressive accounting, and issues with management and past financial reporting. Investors who purchased shares between August 6, 2024, and May 27, 2025, are affected.
Tempus AI Options Trading: A Deep Dive into Market Sentiment
Deep-pocketed investors have shown a bearish sentiment towards Tempus AI (NASDAQ: TEM) through significant options trading activity. While 33% of these investors are bullish, 55% have adopted a bearish stance, with price targets ranging from $35.0 to $95.0. This indicates a notable divergence in market expectations for Tempus AI's stock performance.
Tempus AI, Inc. Stock (TEM) Opinions on FDA Clearance and Recent Price Drop
Discussions around Tempus AI, Inc. (TEM) stock are focused on the company's recent FDA 510(k) clearance for AI-driven diagnostic tools, viewed as a positive for precision oncology. Despite this, the stock recently dropped 9%, fueling debate about its future direction, especially given significant insider selling by the CEO and other executives. Analysts generally maintain "Buy" ratings with a median price target of $87.0, while institutional investors show mixed activity with some increasing and others decreasing their holdings.
TEM Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Tempus AI, Inc. Class Action
Robbins LLP reminds investors of the lead plaintiff deadline in the class action lawsuit against Tempus AI, Inc. The lawsuit alleges that Tempus AI inflated the value of contract agreements, misrepresented its AI capabilities, and engaged in aggressive billing practices. These issues led to a significant drop in Tempus common stock after a report by Spruce Point Capital Management, LLC.
Tempus AI (TEM) Logs First Non-GAAP Profit And Bullish 2025 Outlook Is The Thesis Evolving?
Tempus AI (TEM) recently reported its first non-GAAP profit for Q3 2025 due to momentum in genomics testing and data services, alongside plans for further FDA submissions. The company also projected significantly higher 2025 revenue and positive adjusted EBITDA, indicating successful operational scaling. This positive financial performance and optimistic outlook are reshaping the investment narrative, with a fair value estimated at $91.42, suggesting a 42% upside.
Tempus AI price target lowered to $80 from $90 at BofA
BofA analyst Michael Ryskin has reduced the price target for Tempus AI (TEM) to $80 from $90, maintaining a Neutral rating on the shares. This adjustment is part of an update for Life Sciences & Diagnostic Tools stocks under BofA's coverage, anticipating a normalization of markets in 2026 and a return to spending by Biopharma companies, which would benefit firms with high R&D exposure.
Bank of America Securities Sticks to Their Hold Rating for Tempus AI, Inc. Class A (TEM)
Bank of America Securities reiterated a Hold rating on Tempus AI, Inc. Class A (NASDAQ: TEM) with a price target of $80.00. This follows similar ratings from other firms, while Morgan Stanley maintained a Buy rating. The company reported increased revenue but also an increased GAAP net loss in its latest quarter, and corporate insider sentiment is negative due to increased selling activity.
Tempus AI price target lowered to $80 from $90 at BofA
BofA analyst Michael Ryskin has lowered the price target for Tempus AI (TEM) to $80 from $90, while maintaining a Neutral rating. The adjustment is part of a firm-wide update for Life Sciences & Diagnostic Tools stocks, anticipating a market normalization and a return to spending by Biopharma in 2026. BofA favors companies with higher exposure to research and development.
Tempus AI price target lowered to $80 from $85 at JPMorgan
JPMorgan analyst Casey Woodring has lowered the price target for Tempus AI (TEM) to $80 from $85 while maintaining a Neutral rating on the shares. This adjustment reflects updated models within the life science tools and diagnostics sector.
Tempus AI CFO Rogers James William Sells Shares
Tempus AI CFO and 10% Owner, Rogers James William, sold 19,966 shares of Class A Common Stock on December 11, 2025, for a total of $1,461,479. The sale was executed under a Rule 10b5-1 trading plan at weighted average prices between $72.09 and $74.08. Following this transaction, Rogers James William directly owns 111,250 shares in Tempus AI.
Piper Sandler Keeps Their Hold Rating on Tempus AI, Inc. Class A (TEM)
Piper Sandler analyst David Westenberg maintained a Hold rating on Tempus AI, Inc. Class A (TEM) with an $80.00 price target. This decision comes as Tempus AI reported a quarterly revenue of $334.21 million and a GAAP net loss of $79.98 million for the quarter ending September 30. The company’s analyst consensus is a Moderate Buy with a price target of $90.64.
Tempus AI, Inc. Class A (TEM) Receives a Buy from BTIG
BTIG reiterated a Buy rating for Tempus AI, Inc. Class A (TEM) with a price target of $105.00, according to a report from Mark Massaro on November 26, 2025. The company reported a significant increase in quarterly revenue to $334.21 million, though it also had a GAAP net loss of $79.98 million. Corporate insider sentiment for TEM is negative due to increased selling activity over the past quarter.
Recursion Pharmaceuticals registers 7.1 million shares for Tempus AI resale
Recursion Pharmaceuticals Inc. has filed to register 7,088,742 shares of its Class A common stock for resale. These shares were issued to Tempus AI, Inc. as payment for annual license fees under an existing master agreement between the two companies. This move comes as Recursion Pharmaceuticals, currently trading at $4.37, faces cash burn challenges despite a strong liquidity position, following a Q3 2025 earnings report with an EPS of -$0.36 but a significant revenue miss of $5.18 million against an expected $16.95 million.
Tempus AI, Inc. Stock (TEM) Opinions on FDA Clearance and Earnings Report | TEM Stock News
Tempus AI, Inc. (TEM) has generated significant discussion following FDA 510(k) clearance for its new AI-driven diagnostic tools, particularly in oncology, leading to optimism about its growth. Despite strong revenue growth and raised guidance, the stock experienced a post-earnings decline, and a resurfaced short seller report has added to market caution. Meanwhile, insider trading analysis shows numerous sales and no purchases, while institutional investors have mixed views, with some major shifts in holdings.
Tempus AI CEO Lefkofsky sells shares worth $12.6m
Tempus AI CEO Eric P. Lefkofsky sold Class A Common Stock worth $12.57 million in multiple transactions on November 18 and November 20, 2025. Following these sales, Lefkofsky directly and indirectly holds millions of shares through various entities. The company recently reported strong Q3 2025 earnings and announced a new research study.
Tempus AI COO Fukushima sells $661,870 in stock
Tempus AI COO Ryan Fukushima sold 10,099 shares of Class A Common Stock for approximately $661,870 on November 18, 2025. These sales were to cover tax withholding obligations related to restricted stock units and were not discretionary. Tempus AI is valued at $12.29 billion, with recent positive financial results, though its stock saw a slight decline last week despite significant year-to-date gains.
Tempus AI chief accounting officer sold $120,196 in stock
Tempus AI's Chief Accounting Officer, Ryan M. Bartolucci, sold 1,834 shares of Class A Common Stock for approximately $120,196 on November 18, 2025. This transaction comes as the company's stock experienced a 4.07% decline in the past week but boasts a 94.58% year-to-date gain. Despite a recent price target reduction by Canaccord Genuity, Tempus AI reported strong Q3 2025 earnings, exceeding analyst expectations, and announced a new research study.
Tempus AI Reports Strong Q3 2025 Growth
Tempus AI (TEM) announced strong Q3 2025 earnings, with revenues up 84.7% year-over-year to $334.2 million, driven significantly by its Genomics business. The company also achieved a positive Adjusted EBITDA of $1.5 million and expanded its capabilities through strategic acquisitions and partnerships. Tempus AI projects approximately $1.265 billion in revenue by the end of 2025, fueled by continued investments in AI and precision medicine.
Tempus AI Reports Strong Q3 2025 Financial Growth
Tempus AI, Inc. reported significant Q3 2025 financial growth, with revenue increasing by 84.7% year-over-year to $334.2 million and gross profit improving by 98.4%. The company achieved a positive adjusted EBITDA of $1.5 million despite a net loss, expanded operations through the acquisition of Paige, and received FDA clearance for AI-powered medical devices. Tempus AI also raised its full-year revenue guidance to $1.265 billion, representing approximately 80% growth year-over-year.
TD Cowen Remains a Hold on Tempus AI, Inc. Class A (TEM)
TD Cowen analyst Daniel Brennan maintained a Hold rating on Tempus AI, Inc. Class A (TEM) with an $88.00 price target, following a similar stance by Stifel Nicolaus. The company reported quarterly revenue of $314.64 million and a GAAP net loss of $42.84 million, showing significant revenue growth year-over-year. Insider sentiment is negative, with an increase in insider selling over the past quarter.
Stifel Nicolaus Reaffirms Their Hold Rating on Tempus AI, Inc. Class A (TEM)
Stifel Nicolaus analyst Daniel Arias has reaffirmed a Hold rating for Tempus AI, Inc. Class A (TEM) with an $85.00 price target. This rating comes despite the company reporting strong quarterly revenue of $314.64 million, though it experienced a GAAP net loss of $42.84 million. Insider sentiment for TEM is negative, with an increase in share selling by corporate insiders in the past quarter.
Bank of America Securities Keeps Their Hold Rating on Tempus AI, Inc. Class A (TEM)
Bank of America Securities analyst Michael Ryskin reiterated a Hold rating on Tempus AI, Inc. Class A (TEM) with a price target of $90.00. This follows similar Hold ratings from J.P. Morgan and a Buy rating from Canaccord Genuity. The company recently reported strong quarterly revenue of $314.64 million, though corporate insider sentiment is negative due to increased share selling.
Needham Sticks to Its Buy Rating for Tempus AI, Inc. Class A (TEM)
Needham analyst Ryan MacDonald reiterated a Buy rating for Tempus AI, Inc. Class A (TEM) with a price target of $100.00, implying a potential upside from its current trading levels. This aligns with a Moderate Buy consensus among analysts, with an average price target of $85.50. Despite positive analyst sentiment, corporate insider activity shows a negative trend, with increased selling of shares by insiders in recent months.
Tempus AI Stock (TEM) Slides 6% Overnight: Here's Why The Stock Is Trending
Tempus AI (TEM) shares dropped 6.02% in after-hours trading despite exceeding analyst estimates for its third-quarter revenue and adjusted loss per share, prompting the company to raise its full-year guidance for fiscal 2025. The healthcare technology company reported revenue of $334.21 million and an adjusted loss per share of 11 cents, with adjusted EBITDA turning positive at $1.5 million. Although year-to-date performance has been strong, the stock experienced an overnight slide.
Tempus AI Q3 Highlights: Cathie Wood-, Nancy Pelosi-Owned AI Stock Raises Guidance
Tempus AI reported strong third-quarter financial results, with significant revenue growth and beating analyst estimates on both revenue and adjusted loss per share. The company also announced it had reached positive adjusted EBITDA, an important milestone, and raised its full-year 2025 revenue guidance. The stock has gained popularity in 2025, attracting investments from high-profile figures like Nancy Pelosi and Cathie Wood's ARK Funds.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in Tempus AI, Inc. of Class Action Lawsuit And Upcoming Deadlines - TEM
Pomerantz Law Firm has issued an investor alert regarding a class action lawsuit against Tempus AI, Inc. (TEM). The firm is reminding investors who suffered losses in Tempus AI to contact them about their legal rights and upcoming deadlines, as they investigate potential claims on behalf of investors.
Aspiriant LLC Has $373,000 Stock Holdings in Tempus AI, Inc. $TEM - MarketBeat
Aspiriant LLC significantly reduced its stake in Tempus AI, Inc. by 57.1%, now holding shares valued at $373,000. This comes amidst other institutional investor activity and a notable insider sale by CEO Eric P. Lefkofsky. Tempus AI recently reported a strong revenue increase of 89.5% and beat EPS estimates, with analysts reiterating "buy" ratings and increasing price targets.
Praxis Investment Management Inc. Invests $254,000 in Tempus AI, Inc. $TEM
Praxis Investment Management Inc. acquired a new stake worth approximately $254,000 in Tempus AI, Inc. (NASDAQ:TEM) during the second quarter. This move is part of broader institutional interest, with other major investors like ARK Investment Management LLC and Vanguard Group Inc. also significantly increasing their holdings in the AI-driven precision medicine company. The article also provides stock performance data, analyst ratings, and details on Tempus AI's recent financial results.
Apollon Wealth Management LLC Invests $240,000 in Tempus AI, Inc. $TEM - MarketBeat
Apollon Wealth Management LLC has invested $240,000 in Tempus AI, Inc. by acquiring 3,770 shares in the second quarter. Institutional investors now hold 24.22% of Tempus AI's stock, with significant increases from ARK Investment Management and Vanguard Group. Tempus AI reported a substantial revenue increase of 89.5% year-over-year, totaling $314.64 million, despite a loss of ($0.22) EPS.
Whitehawk Therapeutics (WHWK) Stock Surges on Tempus AI Cancer Drug Partnership - parameter.io
Whitehawk Therapeutics (WHWK) stock surged 67% following the announcement of a multi-year partnership with Tempus AI. This collaboration aims to advance cancer drug research by utilizing Tempus's real-world patient dataset to refine clinical trial designs and support Whitehawk's antibody drug conjugate pipeline, which targets proteins expressed in lung and gynecological cancers. The partnership also seeks to establish concordance between RNA and IHC testing methods for better patient identification.
Whitehawk Therapeutics stock soars after Tempus AI collaboration By Investing.com - Investing.com Canada
The article reports that Whitehawk Therapeutics stock experienced a significant surge following an announced collaboration with Tempus AI. The specific details of the collaboration and the extent of the stock's increase are not provided within the visible content due to a client-side exception.
Whitehawk Therapeutics stock soars after Tempus AI collaboration By Investing.com - Investing.com Nigeria
The article reports on Whitehawk Therapeutics stock soaring following a collaboration with Tempus AI. However, despite the promising title, the current content of the article shows an application error, indicating a loading issue on the investing.com website.
Whitehawk Therapeutics stock soars after Tempus AI collaboration - Investing.com
The article reports that Whitehawk Therapeutics stock increased following a collaboration with Tempus AI. However, due to a client-side application error, the full details of the collaboration and its impact on the stock are not available in the provided content.
Whitehawk Shares Rise After Forming Collaboration With Tempus AI to Advance Oncology Research - MarketScreener
Whitehawk shares rose following the announcement of a collaboration with Tempus AI to advance oncology research. Tempus AI, a technology company specializing in next-generation diagnostics and AI applications in healthcare, especially in oncology and cardiology, is actively involved in numerous partnerships and product developments, including FDA clearances for diagnostic devices. The article also provides detailed financial data, analyst consensus, and recent news regarding Tempus AI.
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research - The Globe and Mail
Tempus AI, Inc. announced a multi-year collaboration with Whitehawk Therapeutics to advance biomarker-driven oncology research and support the development of Whitehawk's oncology pipeline. This partnership will leverage Tempus' proprietary real-world dataset to improve clinical trial designs by focusing on patient populations with high unmet needs, particularly for Whitehawk's antibody drug conjugate (ADC) portfolio. The collaboration aims to utilize data-driven insights to better understand protein target expression, inform indication prioritization, and establish RNA testing as a reliable alternative for identifying appropriate patients for ADC therapies.
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research - The Globe and Mail
Tempus AI, Inc. announced a multi-year collaboration with Whitehawk Therapeutics, Inc. to advance biomarker-driven oncology research. The partnership will leverage Tempus's real-world dataset to support Whitehawk Therapeutics' clinical trial designs and development of its antibody drug conjugate (ADC) portfolio. The goal is to better understand protein target expression for indication prioritization and establish RNA testing as a reliable alternative to IHC methods for identifying appropriate patients.
Tempus AI Hits $100—Are Shares Due for a Pullback?
Tempus AI's shares surged 155% in a short period, reaching $100 for the first time, fueled by device clearances and a presidential order on AI in cancer research. Despite these positive drivers, the article questions whether the rally is sustainable, pointing to an overvalued forward enterprise value to sales ratio compared to industry averages and lacklustre Wall Street forecasts. Investors are advised to consider the potential for a pullback despite strong long-term prospects.
